Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine

被引：0
作者：
Boateng, William K. B. [1 ]
Carlin, Neil [2 ]
Spira, Etan [2 ]
Szabela, Maria E. [3 ]
Ezeh, Kosisochukwu J. [4 ]
机构：
[1] Jersey City Med Ctr, Internal Med, Jersey City, NJ 07302 USA
[2] Jersey City Med Ctr, Gastroenterol & Hepatol, Jersey City, NJ USA
[3] Jersey City Med Ctr, Infect Dis, Jersey City, NJ USA
[4] Marshall Univ, Med Ctr, Internal Med, Huntington, WV USA
来源：
ACG CASE REPORTS JOURNAL | 2025年 / 12卷 / 01期
关键词：
hepatitis; hepatitis B; HIV; cabotegravir; rilpivirine; RILPIVIRINE;
D O I：
10.14309/crj.0000000000001575
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection. We report a case of a 30-year-old man with HIV who transitioned from antiretroviral therapy to CAB/RPV and had confirmed HBV immunity. The patient, though asymptomatic, showed significantly elevated liver function tests (LFTs) before his monthly CAB/RPV injection. He was hospitalized and diagnosed with acute HBV infection. His LFTs improved, and he was taken off CAB/RPV and returned to antiretroviral therapy for the treatment of HIV and HBV. During subsequent follow-ups as an outpatient, the patient's LFTs normalized, and his HBV viral load significantly decreased. This case highlights the potential need for routine HBV testing in patients on CAB/RPV therapy.
引用
收藏
页数：5
相关论文
共 18 条
  • [1] Hepatitis B Virus Reactivation after Switch to Cabotegravir/ Rilpivirine in Patient with Low Hepatitis B Surface Antibody
    Adachi, Eisuke
    Sedohara, Ayako
    Arizono, Kotaro
    Takahashi, Kazuaki
    Otani, Amato
    Kanno, Yoshiaki
    Saito, Makoto
    Koga, Michiko
    Yotsuyanagi, Hiroshi
    [J]. EMERGING INFECTIOUS DISEASES, 2024, 30 (08) : 1668 - 1671
  • [2] Immune-Escape Mutations Are Prevalent among Patients with a Coexistence of HBsAg and Anti-HBs in a Tertiary Liver Center in the United States
    Ali, Mukarram Jamat
    Shah, Pir Ahmed
    Rehman, Khalil Ur
    Kaur, Satinder
    Holzmayer, Vera
    Cloherty, Gavin A.
    Kuhns, Mary C.
    Lau, Daryl T. Y.
    [J]. VIRUSES-BASEL, 2024, 16 (05):
  • [3] clinicalinfo.hiv.gov, What's New: Adult and Adolescent ARV HIV Clinical Guidelines
  • [4] DeHaan E., Use Injectable CAB/RPV LA as Replace ART Virally Suppressed Adults With HIV
  • [5] Update on Adverse Effects of HIV Integrase Inhibitors
    Kolakowska, Agnieszka
    Maresca, Anaenza Freire
    Collins, Intira Jeannie
    Cailhol, Johann
    [J]. CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2019, 11 (04) : 372 - 387
  • [6] Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
    Landovitz, Raphael J.
    Donnell, Deborah
    Clement, Meredith E.
    Hanscom, Brett
    Cottle, Leslie
    Coelho, Lara
    Cabello, Robinson
    Chariyalertsak, Suwat
    Dunne, Eileen F.
    Frank, Ian
    Gallardo-Cartagena, Jorge A.
    Gaur, Aditya H.
    Gonzales, Pedro
    Tran, Ha V.
    Hinojosa, Juan C.
    Kallas, Esper G.
    Kelley, Colleen F.
    Losso, Marcelo H.
    Madruga, J. Valdez
    Middelkoop, Keren
    Phanuphak, Nittaya
    Santos, Breno
    Sued, Omar
    Valencia Huamani, Javier
    Overton, Edgar T.
    Swaminathan, Shobha
    del Rio, Carlos
    Gulick, Roy M.
    Richardson, Paul
    Sullivan, Philip
    Piwowar-Manning, Estelle
    Marzinke, Mark
    Hendrix, Craig
    Li, Maoji
    Wang, Zhe
    Marrazzo, Jeanne
    Daar, Eric
    Asmelash, Aida
    Brown, Todd T.
    Anderson, Peter
    Eshleman, Susan H.
    Bryan, Marcus
    Blanchette, Cheryl
    Lucas, Jonathan
    Psaros, Christina
    Safren, Steven
    Sugarman, Jeremy
    Scott, Hyman
    Eron, Joseph J.
    Fields, Sheldon D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) : 595 - 608
  • [7] Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited
    Leong, Jennifer
    Lin, Derek
    Nguyen, Mindie H.
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2016, 4 (03) : 71 - 75
  • [8] Effect of S-region mutations on HBsAg in HBsAg-negative HBV-infected patients
    Liu, Hui
    Chen, Shuxiang
    Liu, Xin
    Lou, Jinli
    [J]. VIROLOGY JOURNAL, 2024, 21 (01)
  • [9] Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
    Margolis, David A.
    Gonzalez-Garcia, Juan
    Stellbrink, Hans-Juergen
    Eron, Joseph J.
    Yazdanpanah, Yazdan
    Podzamczer, Daniel
    Lutz, Thomas
    Angel, Jonathan B.
    Richmond, Gary J.
    Clotet, Bonaventura
    Gutierrez, Felix
    Sloan, Louis
    St Clair, Marty
    Murray, Miranda
    Ford, Susan L.
    Mrus, Joseph
    Patel, Parul
    Crauwels, Herta
    Griffith, Sandy K.
    Sutton, Kenneth C.
    Dorey, David
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    [J]. LANCET, 2017, 390 (10101) : 1499 - 1510
  • [10] What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
    Mohareb, Amir M.
    Kouame, Menan Gerard
    Nouaman, Marcellin
    Kim, Arthur Y.
    Larmarange, Joseph
    Neilan, Anne M.
    Lacombe, Karine
    Freedberg, Kenneth A.
    Boyd, Anders
    Coffie, Patrick
    Hyle, Emily P.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (03)
12